A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease

  1. Navas-López, V.M.
  2. Pujol Muncunill, G.
  3. Llerena, E.
  4. Navalón Rubio, M.
  5. Gil-Ortega, D.
  6. Varea-Calderón, V.
  7. Sierra Salinas, C.
  8. Martin-de-Carpi, J.
Zeitschrift:
Anales de Pediatria

ISSN: 1695-9531,  1695-4033

Datum der Publikation: 2018

Ausgabe: 88

Nummer: 2

Seiten: 89-99

Art: Artikel

DOI: 10.1016/J.ANPEDI.2017.01.013 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus